Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1992-12-07
1995-04-18
Gerstl, Robert
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514422, 548200, 548518, C07D40706, C07D40306, A61K 3140, A61K 31425
Patent
active
054079500
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to a novel arylalkanoylamine derivative having a prolyl endopeptidase inhibitory action and resistances to hypoxia and amnesia, and a drug for improving mneme, cerebral circulation and cerebral metabolism.
BACKGROUND ART
Senile dementia caused by such cerebral disorders as cerebrovascular disorder, cerebral circulation disorder, cerebral metabolism disorder and memory disturbance has become a social problem in the society with prolonged life-span. Development of drugs useful for improving mneme, cerebral circulation and cerebral metabolism are thus desired. A recent clinical report [M. F. Mazurek et al., Neurology, 36, 1133(1986)] revealed a remarkable decrease of peptides participating in mneme or neurotransmission in brains of senile dementia patients.
Prolyl endopeptidase is an enzyme degrading peptides containing proline, and inactivates vasopressin, thyrotropin releasing hormone, neurotensin and the like, responsible for mneme and neurotransmission, which has propagated mneme and learning tests on the inhibitors of the enzyme. It is known that a compound inhibiting prolyl endopeptidase has resistance to amnesia (Japanese Patent Unexamined Publication No. 62-201877; Japanese Pharmacological Journal, Minanisato, et al., 89, 323(1987); ibid, Taira, et al., 89, 243(1987)).
Drugs improving cerebral circulation, cerebral vasodilators, cerebral metabolism accelerators, and the like are clinically used as drugs for treating cerebrovascular disorders. These drugs, however, exhibit only insufficient improvement in neurological symptoms or inability of daily life in the patients, even though they are recognized to improve subjective symptoms.
Therefore, a drug has been expected which has an action for improving cerebral circulation and cerebral metabolism in combination with an action for improving neurological disorders, such as resistance to amnesia and the like, and an action for improving disorders of movements in daily life.
Thus, the present inventors have made various investigations for research of a compound having a prolyl endopeptidase inhibitory action and an action of improving cerebral metabolism, and have synthesized an imide derivative of amino acid, having resistance to amnesia. The inventors have submitted a patent application (Japanese Patent Unexamined Publication No. 1-2503070). Further research works have been continued thereafter so as to make intensive investigations to generate a novel drug for improving mneme, cerebral circulation and brain metabolism, which drug has an excellent prolyl endopeptidase inhibitory action in combination with an action for improving cerebral circulation and cerebral metabolism. Thus, the present invention has been achieved.
DISCLOSURE OF THE INVENTION
The present invention is to provide an arylalkanoylamine derivative represented by the following general formula (I): ##STR2## (wherein A represents an indanyl, indenyl group, 1,2,3,4-tetrahydronaphthalenyl or benzofuranyl group; m represents an integer of 0 to 5; Z represents a hydroxymethyl, formyl, nitrile, hydroxyiminomethyl, semicarbazonomethyl or dialkoxymethyl group; X and Y may be the same or different, and individually represent methylene group or sulfur atom, provided that the case wherein A represents an indanyl, indenyl, or 1,2,3,4-tetrahydronaphthalenyl group; X and Y both represent a methylene group; Z represents a hydroxymethyl or formyl group, is excluded. Also disclosed is a pharmaceutical composition for improving mneme, cerebral circulation and cerebral metabolism comprising the arylalkanoylamine derivate as an effective ingredient.
BRIEF DESCRIPTION OF DRAWINGS
FIG. 1 is a view depicting the resistance to amnesia of the compound (I) of the present invention. The ordinate represents an amnesic ratio.
BEST MODE FOR CARRYING OUT THE INVENTION
In the general formula (I) representing the compound of the present invention, specific examples of indanyl group, indenyl group, 1,2,3,4-tetrahydronaphthalenyl group and benzofuranyl group are illu
REFERENCES:
patent: 5028604 (1991-07-01), Torizuka
patent: 5212191 (1993-05-01), Toda
Arai Heihachiro
Kato Hisayoshi
Nakata Naoki
Nishioka Hiroyasu
Okubo Akihiro
Gerstl Robert
Zeria Pharmaceutical Co. Ltd.
LandOfFree
Arylalkanoylamine derivative and drug containing the same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arylalkanoylamine derivative and drug containing the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylalkanoylamine derivative and drug containing the same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-67557